Quarterly report · Q3
2160.TEDINET S100SA1Y
Period2023-01-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥20.5bn | 2023-01-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥6.5bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥17.4bn | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥12.8bn | 2022-01-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥4.6bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥6.8bn | 2023-01-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.3bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.5bn | 2022-01-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥490m | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥6.4bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.3bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥768m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.2bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥433m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.2bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥554m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥389m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.1bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥400m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥4.8bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥790m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | −¥868m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥324m | 2022-01-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥126m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥48.5bn | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥33.9bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥36.5bn | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥21.9bn | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥14.1bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥26.6bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.8bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥22.0bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.3bn | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥24.2bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥21.0bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥22.9bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥18.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.0bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥12.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.4bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥4.4bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥393m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥163m | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥3.7bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥4.1bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.9bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥5.0bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥646m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥299m | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥46.61 | 2023-01-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥11.68 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥8.19 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥22.67 | 2022-01-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥8.42 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥46.13 | 2023-01-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥11.33 | 2023-07-01 → 2023-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥8.11 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥22.46 | 2022-01-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥8.28 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 50.0% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.8% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.8% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-09-30 | −¥24m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-09-30 | −¥24m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥24m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥888m |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥18.3bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥18.3bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥5.9bn |
| —segment total | revenue | 2023-01-01 → 2023-09-30 | ¥20.6bn |
| —segment total | revenue external | 2023-01-01 → 2023-09-30 | ¥20.5bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥24m |
| —segment total | segment profit | 2023-01-01 → 2023-09-30 | ¥6.8bn |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-09-30 | −¥38m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-09-30 | −¥38m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥1.7bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥38m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥699m |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥11.0bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥11.0bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥796m |
| —segment total | revenue | 2022-01-01 → 2022-09-30 | ¥12.8bn |
| —segment total | revenue external | 2022-01-01 → 2022-09-30 | ¥12.8bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥38m |
| —segment total | segment profit | 2022-01-01 → 2022-09-30 | ¥1.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 682
| Item | Context | Value | Unit |
|---|---|---|---|
| Issuance of new shares ss IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | 38165000 | JPY |
| Issuance of new shares ss IFRS | CurrentYTDDuration_NonControllingInterestsIFRSMember | － | JPY |
| Issuance of new shares ss IFRS | CurrentYTDDuration | 38165000 | JPY |
| Issuance of share acquisition rights ss IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | 5127000 | JPY |
| Issuance of share acquisition rights ss IFRS | CurrentYTDDuration_NonControllingInterestsIFRSMember | － | JPY |
| Issuance of share acquisition rights ss IFRS | CurrentYTDDuration | 5127000 | JPY |
| Share based payment transactions ss IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | 106374000 | JPY |
| Share based payment transactions ss IFRS | CurrentYTDDuration_NonControllingInterestsIFRSMember | － | JPY |
| Share based payment transactions ss IFRS | CurrentYTDDuration | 106374000 | JPY |
| Issuance cost of share acquisition rights ss IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | -4213000 | JPY |
| Issuance cost of share acquisition rights ss IFRS | CurrentYTDDuration_NonControllingInterestsIFRSMember | － | JPY |
| Issuance cost of share acquisition rights ss IFRS | CurrentYTDDuration | -4213000 | JPY |
| Forfeiture of share acquisition rights ss IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | -21725000 | JPY |
| Forfeiture of share acquisition rights ss IFRS | CurrentYTDDuration_NonControllingInterestsIFRSMember | － | JPY |
| Forfeiture of share acquisition rights ss IFRS | CurrentYTDDuration | -21725000 | JPY |
| Purchase of treasury shares ss IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | -9390000 | JPY |
| Purchase of treasury shares ss IFRS | CurrentYTDDuration_NonControllingInterestsIFRSMember | － | JPY |
| Purchase of treasury shares ss IFRS | CurrentYTDDuration | -9390000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | -657448000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_NonControllingInterestsIFRSMember | 771786000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration | 114338000 | JPY |
| Equity IFRS | CurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember | 24220114000 | JPY |
| Equity IFRS | CurrentQuarterInstant_NonControllingInterestsIFRSMember | 2366497000 | JPY |
| Equity IFRS | CurrentQuarterInstant | 26586611000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 1223079000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 6376072000 | JPY |
| Depreciation expense ope cf IFRS | Prior1YTDDuration | 388148000 | JPY |
| Depreciation expense ope cf IFRS | CurrentYTDDuration | 423733000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1YTDDuration | -940488000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | CurrentYTDDuration | -1974714000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1YTDDuration | 122325000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | CurrentYTDDuration | -256652000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | -117673000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | 260964000 | JPY |
| Bonus allowance ope cf IFRS | Prior1YTDDuration | 11549000 | JPY |
| Bonus allowance ope cf IFRS | CurrentYTDDuration | 26495000 | JPY |
| Finance income and finance costs ope cf IFRS | Prior1YTDDuration | 540127000 | JPY |
| Finance income and finance costs ope cf IFRS | CurrentYTDDuration | 675928000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | -392645000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | -18663000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 834423000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 5513164000 | JPY |
| Interest received ope cf IFRS | Prior1YTDDuration | 40229000 | JPY |
| Interest received ope cf IFRS | CurrentYTDDuration | 126827000 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -9568000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -16992000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1YTDDuration | -1028013000 | JPY |
| Income taxes refund paid ope cf IFRS | CurrentYTDDuration | -1180010000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | -162928000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 4442988000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |